Barinthus Biotherapeutics's total assets for Q4 2024 were $160.33M, a decrease of -15.03% from the previous quarter. BRNS total liabilities were $30.19M for the fiscal quarter, a 3.30% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.